APT 2683
Alternative Names: Malaria vaccine - InflazymeLatest Information Update: 25 Jan 2011
At a glance
- Originator Inflazyme Pharmaceuticals
- Class Parasitic vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Malaria
Most Recent Events
- 21 Apr 2004 Adprotech has been acquired by Inflazyme Pharmaceuticals
- 08 Nov 2002 APT 2683 is available for licensing (http://www.adprotech.co.uk)
- 29 Oct 2001 Preclinical development for Malaria in United Kingdom (Unknown route)